Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06671639

Stanford Program to Accelerate Robotic Children's Surgery

The goal of this clinical trial is to provide additional data to confirm safety and performance of the da Vinci Xi Surgical System in a human clinical setting. This pilot study is intended to provide an initial assessment to evaluate the feasibility, safety, and effectiveness for the utilization of the da Vinci Xi on pediatric and adolescent patients. This clinical trial will be conducted under the auspices of Stanford University's IRB approval.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Lucile Packard Children's Hospital Stanford

Stanford, California, 94305, United States

Location status: Recruiting

Location contact

Brian Nuyen, MD

SUB_INVESTIGATOR

Carolyn Chang, MD

SUB_INVESTIGATOR

Daniel Han, MD

SUB_INVESTIGATOR

Douglas Sidell, MD

SUB_INVESTIGATOR

Erin Grantham, MD

SUB_INVESTIGATOR

Faraz Khan, MD

SUB_INVESTIGATOR

Grant Wells, MS

CONTACT

[email protected]

65-714-4344

Janey S.A. Pratt, MD

SUB_INVESTIGATOR

Kara Meister, MD, FAAP, FACS

SUB_INVESTIGATOR

Kunj Sheth, MD

SUB_INVESTIGATOR

Michael Ma, MD

SUB_INVESTIGATOR

Natalie Lui, MD, MAS

SUB_INVESTIGATOR

Nichole Tyson, MD

SUB_INVESTIGATOR

Patrick Kiessling, MD

SUB_INVESTIGATOR

Stephanie Cizek, MD

SUB_INVESTIGATOR

Tulio Valdez, MD, MSc

SUB_INVESTIGATOR

About this study

Advancements in robotic technology have facilitated the expansion of pediatric robotic surgery, enabling surgeons to perform increasingly complex procedures with greater precision and efficiency. Improved robotic platforms, enhanced imaging modalities, and innovative surgical techniques have contributed to the evolution of pediatric robotic surgery. Moreover, the development of specialized instruments and accessories tailored to pediatric patients, while in limited fashion, has further enhanced the safety and feasibility of robotic-assisted procedures in this population.

The objective of this clinical study is to provide preliminary evidence showcasing that the da Vinci Xi Surgical System is substantially equivalent to existing surgical techniques for the performance of procedures that are the subject of this clinical study. The study will feature two sequential arms with a companion registry of non-robotic participants to compare outcomes and quality of life between each robotic approach and standard of care. The procedures included in each arm are:

  • Arm 1: Sleeve Gastrectomy, Cholecystectomy, Splenectomy, Hysterectomy, endometriosis, ureteral re-implant, and cervical and thoracic tracheoplasty, thymectomy, lobectomy/wedge lung resection, lung segmentectomy
  • Arm 2: Bronchoplasty, Endoscopic Laryngeal/Pharyngeal Suturing, including: Vocal Feminization, Laryngeal Cleft Repair, Endolaryngeal Adjacent Tissue Transfer, Pharyngoplasty; Ileocolonic Resections; Laryngoplasty with or without Graft; Proctectomy with Ileal Pouch-Anal Anastomosis (IPAA)
  • Registry: The registry will recruit patients undergoing the procedures performed in Arm 1 and 2 who will be treated with current standard of care techniques instead of robotic surgery.

Patient enrollment and assessments associated with procedures identified in Arm 1 will be completed prior to any procedures to be performed in Arm 2. The registry will prospectively enroll and evaluate patients undergoing non-surgical procedures at any time during the study period.

Participants will be evaluated from the first pre-operative assessment to 7 weeks post-operative.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is between 6 - 21 years of age (weighing at least 15 kilograms)
  • Subject clinically diagnosed with a medical condition for which one of the study procedures is appropriate therapy and selected as the treatment of choice by the guardian and surgeon.
  • Subject without previous treatment using a robotic surgery device
  • Subject or their guardian is willing and able to provide written informed consent
  • Subject or their guardian is willing and able to comply with the study protocol requirements

Exclusion criteria

  • Subject with uncorrected coagulopathy
  • Subject has clinical requirement for primary open operative procedure
  • Subject is ASA 4 or 5 status
  • Subject is contraindicated for general anesthesia or surgery
  • Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent
  • Subject is pregnant or suspected to be pregnant

Treatment and study plan

da Vinci Xi Robotic Surgery System

Device

The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.

The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system.

Primary outcomes

  1. Performance

    Time frame: Intraoperative

    Performance defined as the conversion to an open approach required to complete the procedure

  2. Number of Subjects With Device-related Serious Adverse Events

    Time frame: Intraoperative

    Safety is determined by measuring the number of subjects that experience device-related serious adverse events

Secondary outcomes

  1. Pediatric Quality of Life Inventory (PedsQL) score

    Time frame: From enrollment to the end of treatment follow-up at 7 weeks post-operative

    Score of questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Karthik Balakrishnan, MD, MPH, FAAP, FACS

CONTACT

[email protected]

(650) 724-4800

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Acronym: SPARCS

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Nov 4, 2024
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.